Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 4/2022

Open Access 14-09-2021 | Gastrectomy | Original Research

The Glasgow Prognostic Score Before Curative Resection May Predict Postoperative Complications in Patients with Gastric Cancer

Authors: Yota Shimoda, Hirohito Fujikawa, Keisuke Komori, Hayato Watanabe, Kosuke Takahashi, Kazuki Kano, Takanobu Yamada, Manabu Shiozawa, Soichiro Morinaga, Kenji Katsumata, Akihiko Tsuchida, Takashi Ogata, Takashi Oshima

Published in: Journal of Gastrointestinal Cancer | Issue 4/2022

Login to get access

Abstract

Purpose

Despite improvements in surgical techniques and devices and perioperative care of gastric cancer (GC), the rate of postoperative complications still has not decreased. If patients at high risk for postoperative complications could be identified early using biomarkers, these complications might be reduced. In this study, we investigated usefulness of the preoperative Glasgow Prognostic Score (GPS) as a predictive factor for complications after surgery in patients with stage II/III GC.

Methods

This study retrospectively analyzed the outcomes of 424 patients who underwent curative surgery for pathological stage II/III GC from February 2007 to July 2019 at a single center. The GPS was assessed within 4 days before surgery. To identify independent risk factors for postoperative complications, univariate and multivariate analyses were performed using a Cox proportional hazards model.

Results

The numbers of patients with a GPS of 0, 1, and 2 were 357, 55, and 12, respectively. The rate of complications after surgery was significantly higher among patients with a GPS of 1 or 2 than among patients with a GPS of 0 (p = 0.008). Multivariate analysis identified a GPS of 1 or 2 as an independent predictive factor for postoperative complications (p = 0.037).

Conclusion

The preoperative GPS may be a useful predictive factor for postoperative complications in patients with stage II/III GC. Being aware of the risk of complications after surgery as indicated by the GPS before surgery may promote safe and minimally invasive surgery that we expect will improve outcomes in patients with a GPS of 1 or 2.
Literature
3.
4.
go back to reference Katai H, Sasako M, Fukuda H, Nakamura K, Hiki N, Saka M, Yamaue H, Yoshikawa T, Kojima K, Takagane A, Fukushima N, Katai H, Saka M, Kojima K, Inokuchi M, Yamada H, Hiki N, Fukunaga T, Yoshiba H, Tokunaga M, Yoshikawa T, Cho H, Mochizuki Y, Misawa K, Uyama I, Kanaya S, Taniguchi K, Imamoto H, Miyashiro I, Tanigawa N, Iwahashi M, Takifuji K, Nishizaki M, Kitanov S, Shiraishi N, Eto T. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer. 2010;13:238–44. https://doi.org/10.1007/s10120-010-0565-0.CrossRefPubMed Katai H, Sasako M, Fukuda H, Nakamura K, Hiki N, Saka M, Yamaue H, Yoshikawa T, Kojima K, Takagane A, Fukushima N, Katai H, Saka M, Kojima K, Inokuchi M, Yamada H, Hiki N, Fukunaga T, Yoshiba H, Tokunaga M, Yoshikawa T, Cho H, Mochizuki Y, Misawa K, Uyama I, Kanaya S, Taniguchi K, Imamoto H, Miyashiro I, Tanigawa N, Iwahashi M, Takifuji K, Nishizaki M, Kitanov S, Shiraishi N, Eto T. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer. 2010;13:238–44. https://​doi.​org/​10.​1007/​s10120-010-0565-0.CrossRefPubMed
5.
8.
go back to reference Jin LX, Sanford DE, Squires MH, Moses LE, Yan Y, Poultsides GA, Votanopoulos KI, Weber SM, Bloomston M, Pawlik TM, Hawkins WG, Linehan DC, Schmidt C, Worhunsky DJ, Acher AW, Cardona K, Cho CS, Kooby DA, Levine EA, Winslow E, Saunders N, Spolverato G, Colditz GA, Maithel SK, Fields RC. Interaction of postoperative morbidity and receipt of adjuvant therapy on long-term survival after resection for gastric adenocarcinoma: results from the U.S. Gastric Cancer Collaborative Ann Surg Oncol. 2016;23:2398–408. https://doi.org/10.1245/s10434-016-5121-7.CrossRefPubMed Jin LX, Sanford DE, Squires MH, Moses LE, Yan Y, Poultsides GA, Votanopoulos KI, Weber SM, Bloomston M, Pawlik TM, Hawkins WG, Linehan DC, Schmidt C, Worhunsky DJ, Acher AW, Cardona K, Cho CS, Kooby DA, Levine EA, Winslow E, Saunders N, Spolverato G, Colditz GA, Maithel SK, Fields RC. Interaction of postoperative morbidity and receipt of adjuvant therapy on long-term survival after resection for gastric adenocarcinoma: results from the U.S. Gastric Cancer Collaborative Ann Surg Oncol. 2016;23:2398–408. https://​doi.​org/​10.​1245/​s10434-016-5121-7.CrossRefPubMed
10.
go back to reference Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ, Participants in the VA National Surgical Quality Improvement Program. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg. 2005;242:326–41; discussion 341–3. https://doi.org/10.1097/01.sla.0000179621.33268.83 Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ, Participants in the VA National Surgical Quality Improvement Program. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg. 2005;242:326–41; discussion 341–3. https://​doi.​org/​10.​1097/​01.​sla.​0000179621.​33268.​83
12.
go back to reference Watanabe H, Hayashi T, Komori K, Hara K, Maezawa Y, Kano K, Shimoda Y, Fujikawa H, Aoyama T, Yamada T, Yamamoto N, Cho H, Ito H, Shiozawa M, Yukawa N, Morinaga S, Yoshikawa T, Rino Y, Masuda M, Ogata T, Oshima T. Impact of postoperative complications on recurrence in patients with stage II/III gastric cancer who received adjuvant chemotherapy with S-1. Anticancer Res. 2020;40:1683–1690. https://doi.org/10.21873/anticanres.14120 Watanabe H, Hayashi T, Komori K, Hara K, Maezawa Y, Kano K, Shimoda Y, Fujikawa H, Aoyama T, Yamada T, Yamamoto N, Cho H, Ito H, Shiozawa M, Yukawa N, Morinaga S, Yoshikawa T, Rino Y, Masuda M, Ogata T, Oshima T. Impact of postoperative complications on recurrence in patients with stage II/III gastric cancer who received adjuvant chemotherapy with S-1. Anticancer Res. 2020;40:1683–1690. https://​doi.​org/​10.​21873/​anticanres.​14120
13.
go back to reference Kasahara N, Sunaga N, Tsukagoshi Y, Miura Y, Sakurai R, Kitahara S, Yokobori T, Kaira K, Mogi A, Maeno T, Asao T, Hisada T. Post-treatment Glasgow Prognostic Score predicts efficacy in advanced non-small-cell lung cancer treated with anti-PD1. Anticancer Res. 2019;39:1455–1461. https://doi.org/10.21873/anticanres.13262 Kasahara N, Sunaga N, Tsukagoshi Y, Miura Y, Sakurai R, Kitahara S, Yokobori T, Kaira K, Mogi A, Maeno T, Asao T, Hisada T. Post-treatment Glasgow Prognostic Score predicts efficacy in advanced non-small-cell lung cancer treated with anti-PD1. Anticancer Res. 2019;39:1455–1461. https://​doi.​org/​10.​21873/​anticanres.​13262
14.
go back to reference Shiba H, Misawa T, Fujiwara Y, Futagawa Y, Furukawa K, Haruki K, Iwase R, Wakiyama S, Ishida Y, Yanaga K. Glasgow prognostic score predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of Vater. Anticancer Res. 2013;33:2715–21.PubMed Shiba H, Misawa T, Fujiwara Y, Futagawa Y, Furukawa K, Haruki K, Iwase R, Wakiyama S, Ishida Y, Yanaga K. Glasgow prognostic score predicts therapeutic outcome after pancreaticoduodenectomy for carcinoma of the ampulla of Vater. Anticancer Res. 2013;33:2715–21.PubMed
15.
go back to reference Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M, Tanaka C, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow prognostic score is the most reliable parameter. Medicine (Baltimore). 2016;95: e3582. https://doi.org/10.1097/MD.0000000000003582.CrossRef Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M, Tanaka C, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow prognostic score is the most reliable parameter. Medicine (Baltimore). 2016;95: e3582. https://​doi.​org/​10.​1097/​MD.​0000000000003582​.CrossRef
18.
go back to reference Inamoto T, Matsuyama H, Sakano S, Ibuki N, Takahara K, Komura K, Takai T, Tsujino T, Yoshikawa Y, Minami K, Nagao K, Inoue R, Azuma H. The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma. Oncotarget. 2017;8:113248–113257. https://doi.org/10.18632/oncotarget.22641 Inamoto T, Matsuyama H, Sakano S, Ibuki N, Takahara K, Komura K, Takai T, Tsujino T, Yoshikawa Y, Minami K, Nagao K, Inoue R, Azuma H. The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma. Oncotarget. 2017;8:113248–113257. https://​doi.​org/​10.​18632/​oncotarget.​22641
21.
go back to reference Brierley JD, Gospodarowicz MK, Wittekind C, Editors. TNM Classification of Malignant Tumors. 2017;8th ed. ISBN:978–1–119–26357–9, West Sussex: Wiley-Blackwell. Brierley JD, Gospodarowicz MK, Wittekind C, Editors. TNM Classification of Malignant Tumors. 2017;8th ed. ISBN:978–1–119–26357–9, West Sussex: Wiley-Blackwell.
34.
go back to reference Fujiwara Y, Shiba H, Furukawa K, Iida T, Haruki K, Gocho T, Wakiyama S, Hirohara S, Ishida Y, Misawa T, Ohashi T, Yanaga K. Glasgow Prognostic Score is related to blood transfusion requirements and post-operative complications in hepatic resection for hepatocellular carcinoma. Anticancer Res. 2010;30:5129–36.PubMed Fujiwara Y, Shiba H, Furukawa K, Iida T, Haruki K, Gocho T, Wakiyama S, Hirohara S, Ishida Y, Misawa T, Ohashi T, Yanaga K. Glasgow Prognostic Score is related to blood transfusion requirements and post-operative complications in hepatic resection for hepatocellular carcinoma. Anticancer Res. 2010;30:5129–36.PubMed
Metadata
Title
The Glasgow Prognostic Score Before Curative Resection May Predict Postoperative Complications in Patients with Gastric Cancer
Authors
Yota Shimoda
Hirohito Fujikawa
Keisuke Komori
Hayato Watanabe
Kosuke Takahashi
Kazuki Kano
Takanobu Yamada
Manabu Shiozawa
Soichiro Morinaga
Kenji Katsumata
Akihiko Tsuchida
Takashi Ogata
Takashi Oshima
Publication date
14-09-2021
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 4/2022
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-021-00689-9

Other articles of this Issue 4/2022

Journal of Gastrointestinal Cancer 4/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.